Vycor Medical’s VBAS Showcased on Cover of Prestigious Journal of Neurosurgery

BOCA RATON, FL / ACCESSWIRE / March 9, 2015 / Vycor Medical, Inc. (“Vycor”) (OTCQB:VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that its VBAS was selected to be on the cover of the March edition of the prestigious Journal of Neurosurgery (JNS). Founded in 1944, the Journal of Neurosurgery is recognized by neurosurgeons and related medical specialists worldwide for its authoritative and cutting-edge clinical articles, laboratory research papers, case reports, literature reviews, technical notes, book reviews and more. The Journal of Neurosurgeryis cited more often than any other journal dedicated to the field of neurosurgery.

The peer-reviewed article from which the cover picture was taken entitled “A 3D Endoscopic Transtubular Transcallosal Approach to the Third Ventricle” was authored by Alireza Shoakazemi et al. of the Department of Neurological Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York. The study concluded: “a transtubular approach [utilizing VBAS] to the third ventricle is feasible and facilitates blunt dissection of the corpus callosum that may minimize retraction injury. This technique also provides an added degree of safety by limiting the free range of instrumental movement. The combination of 3D endoscopic visualization with a clear plastic retractor facilitates safe and direct monitoring of the surgical corridor.” To view the current Journal of Neurosurgery and the article abstract see http://thejns.org/toc/jns/current.

Peter Zachariou, Vycor’s CEO, stated “This peer-reviewed article demonstrates the safety advantages of the device and how it can facilitate surgical procedures. The inclusion of this paper in the JNS provides additional prestigious validation of the VBAS device. We have stated on numerous occasions that we believe continued high quality clinical data supporting the superiority and benefits of our VBAS product range over traditional retractors will help accelerate its adoption and help make it the future standard of care, this is another step towards that goal.”

About Vycor Medical, Inc.

With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB:VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.

Vycor Medical’s ViewSite(TM) Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Canada, China, Europe (EU – Class III), Korea and Japan and is seeking or has partial regulatory approvals in Brazil, India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical’s VBAS see VBAS Video.

NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments. The company’s proprietary Visual Restoration Therapy(R) (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (“TBI”), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any Physician. VRT also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect.

The Company has also developed a therapy called NeuroEyeCoach(TM). The NeuroEyeCoach(TM) therapy is highly complementary to VRT(TM). The two therapies address different visual disabilities each of which results from neurologically-induced vision loss – a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient’s lost visual field; NeuroEyeCoach(TM) is designed to increase the efficiency of eye movement and re-train the patients’ ability to integrate visual information between the left and right hand side. For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

Vycor Medical, Inc Contacts:

6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487
(561) 558-2020
info@vycormedical.com

SOURCE: Vycor Medical, Inc

ReleaseID: 426690